Drugging RAS: Know the enemy
Open accessThe DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
The three RAS oncogenes make up the most frequently mutated gene family in human cancer. The well-validated role of mutationally activated RAS genes in driving cancer development and growth has stimulated comprehensive efforts to develop therapeutic strategies to block mutant RAS function for cancer treatment. Disappointingly, despite more than three decades of research effort, clinically effective anti-RAS therapies have remained elusive, prompting a perception that RAS may be undruggable. However, with a greater appreciation of the complexities of RAS that thwarted past efforts, and armed with new technologies and directions, the field is experiencing renewed excitement that mutant RAS may finally be conquered. Here we summarize where these efforts stand.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“KRAS is the dominant oncogene in PDAC and is altered in more than 90% of tumors, with G12D, G12V, and G12R substitutions being most frequently observed (3, 4).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [3]
In the citing paper
“KRAS is the most frequently mutated oncogene, accounting for approximately 85% of all RAS mutations in 20–25% of all cancers [8–10].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [9]
In the citing paper
“It is difficult to achieve effective competition like protein kinase inhibitors [18, 19].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [19]
In the citing paper
“On the one hand, the affinity of KRAS and GTP is at the pM level, while the concentration of GTP in cells is up to 0.5 μM.”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [19]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
Klionsky, D. J., Abdelmohsen, K., Abe, A., Abedin, M. J., Abeliovich, H., Acevedo Arozena, A., Adachi, H., Adams, C. M., Adams, P. D., Adeli, K., et al. (2016) · Autophagy · doi:10.1080/15548627.2015.1100356 · Cited by 5,894
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
Self-citationGlutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
Son, J., Lyssiotis, C. A., Ying, H., Wang, X., Hua, S., Ligorio, M., Perera, R. M., Ferrone, C. R., Mullarky, E., Shyh-Chang, N., et al. (2013) · Nature · doi:10.1038/nature12040 · Cited by 1,990
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M., & Rosen, N. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,811
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
Pancreatic cancers require autophagy for tumor growth
Yang, S., Wang, X., Contino, G., Liesa, M., Sahin, E., Ying, H., Bause, A., Li, Y., Stommel, J. M., Dell'Antonio, G., et al. (2011) · Genes & Development · doi:10.1101/gad.2016111 · Cited by 1,498
Ras oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467
Cited by
Items 301–400 of 406
Oukkal, M., Bouzid, K., Bounedjar, A., Alnajar, A., Taleb, F. A., Alsharm, A. A., Mahfouf, H., Larbaoui, B., Abdelaziz, A., Ouamer, A., et al. (2022) · The Turkish Journal of Gastroenterology · doi:10.5152/tjg.2022.22106 · Cited by 3
Protein–Protein Interactions in Cancer
Poluri, K. M., Gulati, K., Tripathi, D. K., & Nagar, N. (2023) · Springer eBooks · doi:10.1007/978-981-99-2423-3_2 · Cited by 5
CRISPRing KRAS: A Winding Road with a Bright Future in Basic and Translational Cancer Research
Gong, X., Du, J., Peng, R., Chen, C., & Zhang, Y. (2024) · Cancers · doi:10.3390/cancers16020460 · Cited by 5
“For many years, KRAS mutations have been considered “undruggable”, primarily due to the strong affinity of RAS proteins for GTP, which, when reaching picomolar levels, makes it difficult to find competitive inhibitors with comparable affinity [2,11,12].”
BackgroundRedox, cysteines, and kinases—A triad sustaining myeloid leukemia
Marensi, V. (2024) · Advances in cancer research · doi:10.1016/bs.acr.2024.04.008 · Cited by 3
Moretto, R., Rossini, D., Murgioni, S., Ciracì, P., Nasca, V., Germani, M. M., Calegari, M. A., Vetere, G., Intini, R., Taravella, A., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.24.00329 · Cited by 5
An integrated model for predicting KRAS dependency
(2023) · doi:10.1371/journal.pcbi.1011095 · Cited by 3
“4 colorectal (4%) and pancreatic cancers (1-3%)(4, 6-9).”
BackgroundFilling in the GAPs in understanding RAS
Cox, A. D., & Der, C. J. (2021) · Science · doi:10.1126/science.abl3639 · Cited by 3
Self-citationMeraz, I. M., Wu, S., Xu, Y., Gao, L., Feng, M., Ren, C., Song, R., Zhang, R., Wang, Q., Xi, Y., et al. (2025) · eLife · doi:10.7554/elife.106875.1 · Cited by 6
Benary, G. E., Kilgenstein, F., Koller, S., & Scherkenbeck, J. (2025) · RSC Advances · doi:10.1039/d4ra08503e · Cited by 2
KRAS Mutations in Cancer: From Molecular Insights to Therapeutic Strategies
Zhang, Y., Ma, Y., Zhang, K., Wang, Y., Sun, X., Kan, C., & Han, F. (2025) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000001192 · Cited by 3
McDonald, R. A., Varela-Ramírez, A., & Ashley, A. K. (2025) · Biology · doi:10.3390/biology14080936 · Cited by 4
Yang, F., Li, M., Chen, L., Kang, N., Cao, W., Feng, X., Tang, L., Hu, H., Xi, Y., Liu, B., et al. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109114 · Cited by 2
The Development of Novel Treatment Strategies for Rhabdomyosarcoma
Nakano, K. (2026) · Cancers · doi:10.3390/cancers18040690 · Cited by 2
“The mitogen-activated protein kinase (MAPK) pathway is a cell proliferation pathway involving the direct phosphorylation cascade RAS/RAF-MEK-ERK, and it is known to harbor mutations in many solid tumors [69].”
Li, C., Deng, S., Zhuang, M., Li, T., Lin, L., Zheng, L., Lin, K., Li, D., & Chen, F. (2026) · Oncogene · doi:10.1038/s41388-026-03795-9 · Cited by 2
“Huge efforts have been made to block this pathway by targeting EGFR [4, 5], RAS [6, 7], RAF [8, 9], and MEK [10 – 12].”
K-Ras Plasma Membrane Interactions: A Tractable Therapeutic Target
Cho, K.-J. (2020) · American Journal of Biomedical Science & Research · doi:10.34297/ajbsr.2020.09.001440 · Cited by 2
Zhong, H., Zhang, Y., & Shan, X. (2018) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2018.1491417 · Cited by 2
“To develop therapeutic strategies to block mutant Ras function, scientists have done more than three decades of research efforts (Papke & Der, 2017).”
BackgroundInfluentialBASIC SCIENCE IN ONCOLOGY: YEAR 2017 OVERVIEW
Imyanitov, E. N. I. (2018) · Practical oncology · doi:10.31917/1901001 · Cited by 2
“Несмотря на то, что мутации в генах RAS приводят к конформационным изменениям соответствующих белков-продуктов, создание ингибиторов мутированных молекул KRAS, NRAS, HRAS остаётся нерешённой задачей [28].”
Synthesis, Biological Evaluation, and Binding Mode of a New Class of Oncogenic K‐Ras4b Inhibitors
Jeuken, S., Shkura, O., Röger, M., Brickau, V., Choidas, A., Degenhart, C., Gülden, D., Klebl, B., Koch, U., Stoll, R., et al. (2022) · ChemMedChem · doi:10.1002/cmdc.202200392 · Cited by 2
Ou, L., Cai, X., Zeng, W., Huang, L., Deng, Q., Tang, H., Chen, Z., Zhou, H., Lin, Y., Liu, L., et al. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-22-829 · Cited by 2
“Single-point testing can also be used, but other than the common mutations with treatment available, it is necessary to detect other genes in specific populations, such as KRAS (23,24).”
Development of highly potent and selective oncogenic KRASG12D PROTAC degraders
Mao, Y., Wei, P., Wei, T., Wang, Y., Qi, Z., Cai, X., Jia, C., Zhao, Z., Li, B., Qiao, M., et al. (2025) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2025.100296 · Cited by 1
Vitale, A., Marafioti, M., Galassi, T., Madonia, G., Moro, M., & Dubois, M. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105396 · Cited by 2
Heidemann, S. R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-55227-1.00002-8 · Cited by 1
Exploring Protein-Ligand and Protein-Protein Interactions
Skern, T. (2018) · Learning materials in biosciences · doi:10.1007/978-3-319-76858-8_6 · Cited by 1
Discovery of small molecules blocking oncogenic K-Ras activity
Kovar, S. E. (2018) · Journal of Bioresource Management · Cited by 1
Stability of the Phosphotriester PDE6D Inhibitors
Rosenqvist, P., Sabt, A., Dyunyasheva, V., Abankwa, D., Virta, P., & Ora, M. (2021) · ChemistrySelect · doi:10.1002/slct.202004426 · Cited by 1
Development of PD3 and PD3-B for PDEδ inhibition to modulate KRAS activity
Lee, J., Lee, H. J., Lee, Y., Lim, B., Gam, J., Oh, D., & Lee, J. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2086865 · Cited by 1
“100 mM PD3-B (5) was initially incubated with NeutrAvidin resin before incubation with bacterial lysate (150 mg) overexpressing PDEd.”
BackgroundMethodInfluentialOncogenic Proteomics Approaches for Translational Research and HIV-Associated Malignancy Mechanisms
Alvarez-Rivera, E., Ortiz-Hernández, E. J., Lugo, E., Lozada-Reyes, L. M., & Boukli, N. M. (2023) · Proteomes · doi:10.3390/proteomes11030022 · Cited by 1
“This is largely due to lack of known genetic alterations in the key oncogenic signaling pathways and the difficulty of targeting oncogenic mutations (KRAS mutations) [67,76,77].”
BackgroundSmall-Molecule Inhibitors of Protein–Protein Interactions as Therapeutics
Poluri, K. M., Gulati, K., Tripathi, D. K., & Nagar, N. (2023) · Springer eBooks · doi:10.1007/978-981-99-2423-3_7 · Cited by 1
Lin, Y., Xiong, G., Xia, X., Yin, Z., Zou, X., Zhang, X., Zhang, C., & Ye, J. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1335093 · Cited by 1
“In mouse models, ablation of RAS oncogenes results in dramatic tumor regression (Papke and Der, 2017).”
BackgroundAn updated patent review of SOS1 inhibitors (2022–present)
Zhou, G., Zhou, C., Ma, X., Xu, J., Zhou, Z., Xu, T., Zheng, M., & Zhang, S. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2419825 · Cited by 1
Cooperation between oncogenic NRF2 and wild-type HRAS promotes progression of breast cancer
Kim, S., Saeidi, S., Cho, N., Lee, H., Han, W., Kim, K. P., & Surh, Y. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111920 · Cited by 1
Brandt, R., Sell, T., Lüthen, M., Uhlitz, F., Klinger, B., Riemer, P., Giesecke-Thiel, C., Schulze, S., El-Shimy, I. A., Kunkel, D., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/340844 · Cited by 1
Delivering a RAS protease halts tumor growth
Vidimar, V., Melnyk, R. A., & Satchell, K. J. F. (2020) · Oncotarget · doi:10.18632/oncotarget.27714 · Cited by 1
Basu, S., Luke, B. T., Karim, B. O., Martín, N. C. R., Lockett, S., Das, S., Andrésson, Þ., Saylor, K. L., Kozlov, S. V., Bassel, L., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.05.487175 · Cited by 1
Meraz, I. M., Wu, S., Xu, Y., Gao, L., Feng, M., Ren, C., Song, R., Zhang, R., Wang, Q., Xi, Y., et al. (2025) · eLife · doi:10.7554/elife.106875 · Cited by 2
Papers of note in Science 355 (6330)
VanHook, A. M. (2017) · Science Signaling · doi:10.1126/scisignal.aan2405
Targeting Protein-Protein Interactions in Small GTPases
Liu, J., Kang, N., Zhao, Y., & Zhu, M. (2018) · Springer eBooks · doi:10.1007/978-981-13-0773-7_12
Blocking KRAS Signaling for the Treatment of Lung Cancer: Mission Possible?
Horio, Y. (2018) · Haigan · doi:10.2482/haigan.58.953
Tuladhar, A. (2018) · FIU - Digital Commons (Florida International University) · doi:10.25148/etd.fidc006857
Zeitouni, D. (2017) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/h48y-k278
Development of split luciferase complementation probes sensing KRAS/effector interaction
Miyamoto, K., Ishihara, K., & Sawa, M. (2019) · Translational and Regulatory Sciences · doi:10.33611/trs.1_40
“Despite the long-term intensive efforts to develop pharmacological inhibitors of RAS mutants, RAS proteins have traditionally been deemed “undruggable” because no clinically effective anti-RAS therapy has been found until recently [1].”
BackgroundInfluentialGao, Q., Ouyang, W., Kang, B., Han, X., Xiong, Y., Ding, R., Li, Y., Wang, F., Huang, L., Chen, L., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/807578
Garrido, C. M. (2018) · Journal of Bioresource Management
RAS-Mutationen in der molekularen Tumorkonferenz
Schäfer, R. (2019) · Der Pathologe · doi:10.1007/s00292-019-00702-w
A chemically-controlled system for activating RAS GTPases
Dieter, E. M., & Maly, D. J. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.10.033 · Cited by 3
A Novel Strategy for Identifying Non-covalent KRas Inhibitors
Zhao, H., Sabio, M. L., Topiol, S., Huang, K., Tanaka, N., Chu, W., Gubler, U., & Tolias, P. P. (2020) · Medical Research Archives · doi:10.18103/mra.v8i6.2137
Ras and Ras Signaling as a Therapeutic Target in Cancer
Sliker, B. H., & Campbell, P. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00006-2
Characterizing the critical role of metabolic and redox homeostasis in colorectal cancer
Frodyma, D. E. (2020) · DigitalCommons@UNMC
Genomic Alterations of KRAS and NRAS in B&H Colorectal and Non-small Cell Lung Cancer Patients
Smajović, L.-N., Pećar, D., Salihefendić, L., Hromić‐Jahjefendić, A., & Konjhodžić, R. (2021) · World Congress on Medical Physics and Biomedical Engineering, September 7 - 12, 2009, Munich, Germany · doi:10.1007/978-3-030-73909-6_69
Untersuchung synthetischer Letalität in Vincristin-resistenten Neuroblastomzellen
Zeitz, K. (2021) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.64012
El‐Deiry, W. S., & Borerro, L. H. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736084541.793562166
Schulz, W. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-16286-2_4
Data from Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing
Sayed, S., Sidorova, O. A., Hennig, A., Augsburg, M., Vesga, C. P. C., Abohawya, M., Schmitt, L. T., Sürün, D., Stange, D. E., Mircetic, J., et al. (2023) · doi:10.1158/0008-5472.c.6514029.v1
Hanley, K. L., Liang, Y., Wang, G., Lin, X., Yang, M., Karin, M., Fu, W., & Feng, G. (2023) · doi:10.1158/1541-7786.c.6545618.v1
A Review of the in Silico Design and Development Approaches of Ras-Specific Anticancer Therapeutics
Motiei, P., Heidari, H. R., Hejazi, M. S., Molavi, O., & Aghdam, E. M. (2023) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-023-10578-3
“The Ras isoforms K-Ras, H-Ras, and N-Ras are the three most frequently mutated Ras isoforms in cancer; however, each gene’s role varies by type of cancer (Papke and Der 2017).”
Wang, J., Shen, H., Jiang, Y., & Meng, J. (2024) · Research Square · doi:10.21203/rs.3.rs-3787479/v1
Schulz, W. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-42806-7_4
CasRx-Based Kras G12D Silencing for In Vivo Tumor Inhibition in Spontaneous Lung AdenocarcinomaPreprint
Wang, X., Liu, F., Xu, L., Shi, Y., Zhang, L., Chen, F., Gu, S., Jin, Z., Zhou, H., Li, T., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4041534/v1
Kasack, K., Metzger, P., Koch, H., Klinger, B., Malek, A. V., Tchernitsa, O. I., Gross, A., Wruck, W., Győrffy, B., Küster, B., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.04.597297
Gill, A. L., & Marx, M. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00017-6
Meraz, I. M., Wu, S., Xu, Y., Gao, L., Feng, M., Ren, C., Song, R., Zhang, R., Wang, Q., Xi, Y., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.18.643954
Song, H., Wang, G., Gao, G., Xia, H., Jiao, L., & Wu, K. (2025) · Cancers · doi:10.3390/cancers17091485
“RAS proteins were historically considered difficult due to their smooth surface and the high affinity of GTP binding [107].”
Codenotti, S., Marampon, F., Megiorni, F., Cattaneo, C. G., Gastaldello, S., Pozzo, E., Sampaolesi, M., Rota, R., Keller, C., & Fanzani, A. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2025.145 · Cited by 3
The Important Role of Survivin in KRAS-driven Pancreatic Cancer
Chang, W.-H. (2021) · eCommons (Cornell University) · doi:10.7298/dmrv-k734
Reinhardt, H. C., Medizin, U. K. K. I. F. I., Thomas, R. K., Dobbelstein, M., & Erber, J. (2021) · PUBLISSO (German National Library of Medicine) · doi:10.4126/frl01-006427091
Marullo, S. A. (2022) · Papyrus : Institutional Repository (Université de Montréal) · doi:10.71781/25962
Nindra, U., Hong, J. H., Hong, M., Lim, S. H.-S., Asghari, R., Farzin, M., Rutland, T., Chantrill, L., Brungs, D., Wong, M. K., et al. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101103 · Cited by 2
Hadi, N. A., Ramadhan, R. S., Al-Azzawi, K. S., Algafari, R. N., Rasheed, S. S., & Khalaf, R. A. (2026) · OBM Genetics · doi:10.21926/obm.genet.2601328
Criblage de molécules stimulant l'immunité innée et acquise
Mahtal, N. (2017) · theses.fr (ABES) · doi:10.70675/a8da595bz01bez41b6z9786zdea2a4643825
Cell penetrating and interfering peptides as new cancer therapy
Zhang, X. (2017) · theses.fr (ABES) · doi:10.70675/b2053021ze747z4f1azacb7z8a87a14ec9e3
Unlocking drug sensitivity in KRAS
MingCong, L. I., YueSong, Z. H. O. U., Qiao, T. D., QingLin, B. A. I., & Li, C. (2026) · Scientia Sinica Vitae · doi:10.1360/ssv-2025-0279
Pandey, D., Dwivedi, S., & Roy, K. K. (2026) · Molecular Diversity · doi:10.1007/s11030-026-11554-x
“To gain mechanistic insights, we evaluated the impact of Indiru-bin and Rubimaillin on two major downstream effectors of KRAS: the PI3K/AKT/mTOR and RAF/MEK/ERK pathways [43].”
Zhu, G., Pei, L., Li, J., Zhang, C., Ye, D., Li, J., Tang, Q., Huang, H., Xu, H., & Bi, F. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117338
Wang, P. P., Yuan, Y., Yang, L., Sun, R., Bo, W., Ma, Z., Qin, S., Chen, Y., Li, M., Liu, S., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00242
Li, R., Xu, X., Zhang, W., & Zhan, Y.-Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1843505
Zhou, C., Zhu, Y., Yang, C., Gao, Y., Lu, J., & Ming, D. (2026) · Pharmaceuticals · doi:10.3390/ph19050753
“Among these, G12 mutations account for 89% [13–15], and G12D is the most common subtype in PDAC (45”
Zha, J., Wang, S. L., Zhou, H., wang, W., Xu, C., Fu, S., Tan, S., zhou, J., Wang, L. S., weng, J., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9900947/v1
Arshinnikova Anna, S., Tararina Valeria, V., Zuban Polina, A., Leshcheva Elizaveta, A., Bogdanova Irena, V., Fishchenko Ekaterina, A., Nadaraia Mariam, S., Zeynalova Sabina, I., Gorodkova Maria, E., Kamurzoev Ismail, A., et al. (2026) · International Journal of Science and Research Archive · doi:10.30574/ijsra.2026.20.1.1495
Chien, Y.-T., Huang, J., Zhao, Y., Zhou, Y., Zhang, M., & Mu, Q. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167285
“Mutant KRAS constitutively activates downstream signaling pathways, including mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase–AKT (PI3K–AKT) pathways, promoting uncontrolled proliferation, survival, and resistance to apoptosis [16].”
Xie, J., Wang, S., Liu, J., Zhang, Y., Zhu, H., Cui, R., Yao, Y., Yu, W., & Hou, P. (2026) · APOPTOSIS · doi:10.1007/s10495-026-02429-5
KRAS in Colorectal Cancer: Tumorigenesis, Surgical Implications and Evolving Treatment Target
Iftikhar, S., Xiao, A. H., Jin, Z., & Aly, E. H. (2026) · Current Oncology · doi:10.3390/curroncol33090514
“These factors collectively hinder the development of effective competitive inhibitors [65].”
Adhao, V., & Patil, S. N. (2026) · INNOSC Theranostics and Pharmacological Sciences · doi:10.36922/itps026270024
DeLiberty, J. M., Kong, F. Y., Yu, Q., Sindoni, N., Lin, J., Kang, K., Kim, E. Y., Chen, S., Padhye, A., Coker, O., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.01.756025
Khattab, M. S., Mehtab, M. A., & Khan, R. (2026) · doi:10.3390/chemproc2026022007
Li, M.-X., Chen, L.-L., Huang, S.-J., Shi, H., Kang, N., Tang, L., Zou, Z., Xue-jin, F., Xi, Y.-L., Ruan, Y.-D., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119427
BindingDB (2024) · UC San Diego · doi:10.7270/q2nc65pm
BindingDB Entry 50014692: Discovery of a Bicyclic Peptidyl Pan-Ras Inhibitor.
BindingDB (2022) · UC San Diego · doi:10.7270/q22v2kz6
BindingDB (2021) · UC San Diego · doi:10.7270/q2rn3cfh
BindingDB (2024) · UC San Diego · doi:10.7270/q2m61qmd
BindingDB Entry 50010526: Identification of the Clinical Development Candidate
BindingDB (2021) · UC San Diego · doi:10.7270/q2g164c5
BindingDB (2020) · UC San Diego · doi:10.7270/q2cv4mff
Metadata
- Authors
- Papke, B., & Der, C. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Der, Channing J.
- Venue
- Science
- Published
- 2017-03-17
- Volume
- 355
- Issue
- 6330
- Pages
- 1158-1163
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2597182072
- Cited by
- 399
- References
- 51
- Citations by year
- 2026: 25 · 2025: 37 · 2024: 45 · 2023: 30 · 2022: 46 · 2021: 52 · 2020: 48 · 2019: 51 · 2018: 45 · 2017: 20
- FWCI
- 4.24
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- U.S. Department of Defense (W81XWH-15-1-0611)
- National Cancer Institute (CA042978, CA175747, CA199235, CA203657)
- Pancreatic Cancer Action Network
- Lustgarten Foundation
- Deutsche Forschungsgemeinschaft (PA 3051/1-1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- oncogenic Ras, anticancer drug development, Ras signaling
- MeSH terms
- Antineoplastic Agents, Cell Membrane, Enzyme Inhibitors, Humans, Mutation, Neoplasms, Drug Design, ras Proteins, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.